Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31550488 | 0.79 | SIRT2 (0.49) | SIRT2CTSSCTSK | |
| SCHEMBL26496891 | 0.79 | DPP4 (0.40) | DPP4DPP8DPP9DPP7SIRT2 | |
| SCHEMBL31550493 | 0.78 | SIRT2 (0.33) | SIRT2 | |
| SCHEMBL24642760 | 0.75 | DPP4 (0.33) | DPP4DPP8DPP9DPP7F10 | |
| SCHEMBL30705433 | 0.74 | GAA (0.40) | — | |
| SCHEMBL26528469 | 0.74 | DPP4 (0.45) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL31550501 | 0.71 | TLR2 (0.42) | SIRT2 | |
| SCHEMBL24642327 | 0.70 | SIRT2 (0.34) | SIRT2 | |
| SCHEMBL24642917 | 0.69 | DPP4 (0.48) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL24642903 | 0.67 | SIRT2 (0.34) | SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332272-A1 | PREPARATION METHOD FOR DRUG LINKER CONJUGATE AND INTERMEDIATE THEREOF | MEDILINK THERAPEUTICS SUZHOU CO LTD (CN) | 2025-10-30 | — | — | US | disclosed |
| EP-4534104-A1 | PREPARATION METHOD FOR DRUG LINKER CONJUGATE AND INTERMEDIATE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2025-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332272-A1 | PREPARATION METHOD FOR DRUG LINKER CONJUGATE AND INTERMEDIATE THEREOF | SI, PAICS, FURIN | DPP4 1853/4885DPP8 1638/4885DPP9 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.